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Background WHO has played a leading role in the formulation and promulga-
tion of standard criteria for the diagnosis of coronary heart disease
and myocardial infarction since early 1970s.
Methods The revised definition takes into consideration the following:
well-resourced settings can use the ESC/ACC/AHA/WHF definition,
which has new biomarkers as a compulsory feature; in resource-
constrained settings, a typical biomarker pattern cannot be made a
compulsory feature as the necessary assays may not be available;
the definition must also have provision for diagnosing non-fatal
events with incomplete information on cardiac biomarkers and
the ECG; to facilitate epidemiologic monitoring definition must
recognize fatal events with incomplete or no information on cardiac
biomarkers and/or ECG and/or autopsy and/or coronary
angiography.
Results Category A definition is the same as ESC/ACC/AHA/WHF definition
of MI, and can be applied to settings with no resource constraints.
Category B definition of MI is to be applied whenever there is
incomplete information on cardiac bio-markers together with symp-
toms of ischaemia and the development of unequivocal pathological
Q waves. Category C definition (probable MI) is to be applied when
individuals with MI may not satisfy Category A or B definitions
because of delayed access to medical services and/or unavailability
of electrocardiography and/or laboratory assay of cardiac biomar-
kers. In these situations, the term probable MI should be used
when there is either ECG changes suggestive of MI or incomplete
information on cardiac biomarkers in a person with symptoms of
ischaemia with no evidence of a non-coronary reason.
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Conclusions This article presents the 2008–09 revision of the World Health
Organization (WHO) definition of myocardial infarction (MI) devel-
oped at a WHO expert consultation.
Keywords Myocardial infarction, epidemiology, clinical diagnosis, ischeamic
heart disease, atherosclerosis
Introduction
Cardiovascular disease is a global public health
problem contributing to 30% of global mortality and
10% of the global disease burden.1,2 In 2005, from a
total of 58 million deaths worldwide, 17 million
were due to cardiovascular disease and, among them,
7.6 million were due to coronary heart disease.3,4
Myocardial infarction (MI) is one of the five main
manifestations of coronary heart disease, namely
stable angina pectoris, unstable angina pectoris, MI,
heart failure and sudden death. The phrase ‘acute
coronary syndromes’ includes unstable angina,
non-ST-elevation MI, ST-elevation MI and sudden
cardiac death. In epidemiological studies, the incidence
of MI in a population can be used as a proxy for
estimating the coronary heart disease burden.
The burden of cardiovascular disease is rising both
in high-income countries and low- and middle-
income countries (LMICs) because of ageing popula-
tions, but the burden is greater in LMICs because of
much larger population sizes and widespread
exposure to increasing levels of risk factors such as
unhealthy diet, physical inactivity, obesity, tobacco
use, diabetes, raised blood pressure and abnormal
blood lipids. Often in LMICs there is a lack of infor-
mation on the role of risk factors. It has been shown
that risk factors for cardiovascular disease are largely
similar in high-income countries as in LMICs.5 The
consequences of globalization and urbanization are
also contributory factors.3 In order to track the
trends of this global epidemic, the incidence, preva-
lence and mortality of coronary heart disease need to
be monitored. Case definitions for different presenta-
tions of coronary heart disease are required. They
need to be scientifically valid, consistent when applied
across countries, generally applicable and robust.
The new definition of MI by the World Health
Organization (WHO) should facilitate epidemiological
monitoring, coding of the clinical diagnosis, validity
of death certificates and disease classification. Such
a standardized case definition of MI is of special
importance since it is a means to obtain reliable and
comparable data for evaluation of the effectiveness of
prevention and curative strategies in countries with
widely varying health systems. The definition has
implications for epidemiology, disease monitoring,
content of registries, clinical research studies, clinical
trials, quality assurance, economic analysis, medico-
legal disputes and estimation of health-care costs. At
the individual level, the diagnosis of MI has a major
impact on physical and psychological health and often
on family, legal and insurance matters.
Definition of MI
MI is defined by the demonstration of myocardial cell
necrosis due to significant and sustained ischaemia. It
is usually, but not always, an acute manifestation of
atherosclerosis-related coronary heart disease. MI
results from either coronary heart disease, which
implies obstruction to blood flow due to plaques in
the coronary arteries or, much less frequently, to
other obstructing mechanisms (e.g. spasm of plaque-
free arteries). Plaques are always a consequence of
atherosclerosis. Coronary heart disease may relate to
stable or unstable underlying plaques. Unstable
plaques are characterized by activated inflammation
of the vascular wall at the site of plaques. There
may be erosion, fissuring or even rupture of the
plaques. Platelets can accumulate at the site of an
active plaque, further obstructing blood flow and
leading to unstable angina. Rupture of atherosclerotic
plaques usually leads to acute coronary syndromes or
overt MI. Atherosclerotic plaques may expand slowly
but more often enlarge in steps. After platelets
accumulate on the surface, the healing process adds
a further layer to the plaque, which eventually can
become fibrous, lipid laden and calcified.
The clinical presentation of MI varies from a minor
coronary event to life-threatening clinical situations or
sudden death. Those who survive the initial event are
vulnerable to repeat attacks of MI. As alluded to
above, information on the distribution of MI in a
population, if standardized, provides useful informa-
tion regarding the burden of coronary artery disease
in a population. If standardized data can be collected
on sudden coronary death and incident and repeat
episodes of MI, then the totality of this burden can
be determined.
WHO has played a leading role in the formulation and
promulgation of standard criteria for the diagnosis of
coronary heart disease and MI.6–9 In the 1970s, the case
definition of MI used in international collaborative
projects was based on the WHO European AMI registry
criteria.7 This definition was further revised in a joint
report with the International Society and Federation of
Cardiology in 1979.8
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The WHO European Myocardial Infarction registry
criteria7 were based on clinical history, findings on
the electrocardiogram (ECG), enzyme measurements
in blood and postmortem findings. MI was diagnosed
in the presence of one of the following:
(i) ECG showing unequivocal pathological Q waves
and/or ST segment elevation or depression in
serial recordings;
or
(ii) history of typical or atypical angina pectoris,
together with equivocal changes on the ECG
and elevated enzymes;
or
(iii) history of typical angina pectoris and elevated
enzymes with no changes on the ECG or not
available;
or
(iv) fatal cases, whether sudden or not, with naked-
eye appearances of fresh MI and/or recent
coronary occlusion at necropsy (antemortem
thrombus, haemorrhage into an atheromatous
plaque or embolism).
In the revised WHO criteria used in the multicentre
MONICA project conducted in the 1970–80s,
Minnesota coding was used to evaluate the ECG
rather than the subjective methods of the above
criteria.9–11 Explicit coding rules were defined for
enzymes and symptoms. Most importantly, all
possible situations with incomplete information on
the ECG, enzymes or symptoms were covered.
Since then, advances in diagnostic technology,
including new biomarkers and imaging methods
that are more specific and/or sensitive, have enabled
the detection of even minor myocardial cell necrosis.
These advances called for a re-evaluation of the
case definition of MI. In 2000, the European Society
of Cardiology (ESC) and the American College of
Cardiology (ACC) revised the definition of MI.12 In
2003, the American Heart Association (AHA) in col-
laboration with the World Heart Federation (WHF),
ESC, Centers for Disease Control and Prevention and
the National Heart Lung and Blood Institute issued a
scientific statement on the case definitions of acute
coronary heart disease in epidemiology and clinical
research studies for evaluating trends and event
rates on the basis of retrospective surveillance.13
More recently, the ESC, ACC and AHA in collabor-
ation with the WHF published and updated the
2000 ESC/ACC consensus document.14 This revised
definition makes the detection of a rise and/or fall
of cardiac biomarkers in the clinical setting of myo-
cardial ischaemia essential for the diagnosis of MI.
New cardiac biomarker assays are more costly than
older assays and are not accessible to large segments
of the population in LMICs where the incidence of
coronary heart disease is rising. The new definition
cannot easily be used to identify non-fatal events
with incomplete information on cardiac biomarkers,
or fatal events occurring in or out of hospital with
incomplete information on cardiac biomarkers, with
or without only one ECG recording and/or availability
of autopsy data and/or information from coronary
angiography. Furthermore, events in patients reaching
hospital, although suspect, may not have complete
clinical information, including measurement of the
new biomarkers. A major problem with the revised
definition14 is that although it is quite appropriate
for high-resource settings, it falls short of the clinical
and epidemiologic needs in low-resource settings.
New or revised definitions need to embrace recent
advances in medical science; however, there must be
provision in any new definition for persons in LMICs
and even resource-constrained settings in developed
countries to be able to diagnose MI and monitor
rates of MI. Such data are necessary in order to
make epidemiological comparisons within and be-
tween populations in a standardized manner.
Comparisons are important for two reasons. First,
the largest increase in the cardiovascular disease
burden over the next 10 years will occur in LMICs,
where there are resource constraints. Second, there is
a social gradient in relation to coronary heart disease
in developed countries, with higher prevalence rates
and fatality rates in people in lower social classes,
who often have suboptimal access to healthcare.2,3
Monitoring MI rates in disadvantaged sectors is
essential to address such disparities.
New biomarkers (e.g. troponin), although more spe-
cific and sensitive, are generally not available as rou-
tine biochemical tests in the public health systems of
most LMICs. However, assays for the new biomarkers
may be available, even in low-income countries,
within the private medical sector at a price that is
unaffordable for majority of people. As one-third of
the world population lives on <2 USD a day and
out-of-pocket expenditures for health can be as high
as 80% in developing countries, worldwide access to
these assays is limited and depends on social deter-
minants.3,15,16 Making these assays a compulsory fea-
ture of the definition of MI has the potential risk of
further widening already existing health inequalities
in the cardiovascular domain.16 Blood samples may
not be available if the patient dies outside hospital
or soon after arriving at hospital, and laboratory facil-
ities may not be available at all in many settings in
LMICs. The new definition accepts one measurement
of troponin only if the value exceeds the decision level
for MI. If this is not the case, demonstration of a
rise and fall of such levels will require at least two
measurements, which may be unaffordable to health
systems and people in many low-resource settings.
For these reasons, it was felt necessary to allow
some flexibility in the definition of MI in order to
broaden its applicability to settings with high resources
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as well as to settings with resource constraints.
In 2008, WHO initiated a process to review the WHO
definition of MI addressing the above issues. The
process consisted in a consultation of experts held
at WHO in Geneva, on 16–17 April 2008 followed in
2009 for an extensive peer review. The definition may
change again in the future as science advances and
blood tests of whatever nature become inexpensive
and more widely available in countries with limited
resources.
WHO definition and diagnostic criteria of MI
Category A definition and diagnostic criteria of MI.
ICD-10 code: I 21
The same definition as the ESC/ACC/AHA/WHF
definition; for use in settings with no resource
constraints.14
The term MI should be used when there is evidence
of myocardial necrosis in a clinical setting consistent
with myocardial ischaemia (no evidence of a cause
other than ischaemia). Any one of the following
criteria meets the diagnosis for MI.
(i) Detection of rise and/or fall of cardiac biomarkers
(preferably troponin) with at least one value
above the 99th percentile of the upper reference
limit together with evidence of myocardial is-
chaemia with at least one of the following:
(a) symptoms of ischaemia (include various
combinations of chest, upper extremity, jaw
or epigastric discomfort with exertion or at
rest; the discomfort usually lasts 420 min,
often is diffuse, not localized, not positional,
not affected by movement of the region and
it may be accompanied by dyspnoea, dia-
phoresis, nausea or syncope);
(b) ECG changes indicative of new ischaemia
[new ST-T changes or new left bundle
branch block (LBBB)–Minnesota codes:
ST-depression 4.1; 4.2; ST-elevation 9.2;
LBBB 7.1];
(c) development of pathological Q waves in the
ECG (Minnesota codes: 1.1.1 through 1.2.5
plus 1.2.7),17 including:
(1) no unequivocal pathological Q waves in
the first ECG or in event set of ECG(s)
followed by a record with a pathologic-
al Q wave or
(2) any Q wave in leads V2–V35 0.02 s or
QS complex in leads V2 and V3 or
Q wave 50.03 s and 50.01 mV deep
or QS complex in leads I, II, aVL, aVF or
(3) V4–V6 in any two leads of a contiguous
lead grouping (I, aVL, V6:V4–V6: II, III,
aVF).
(d) imaging evidence of new loss of viable
myocardium or new regional wall motion
abnormality.
or
(ii) Sudden unexpected cardiac death, involving
cardiac arrest, often with symptoms suggestive
of myocardial ischaemia (ischaemic symptoms
include various combinations of chest, upper
extremity, jaw or epigastric discomfort with ex-
ertion or at rest; the discomfort usually lasts
420 min, often is diffuse, not localized, not
positional, not affected by movement of the
region, and it may be accompanied by dys-
pnoea, diaphoresis, nausea or syncope.) and
accompanied by
(a) presumably new ST elevation or new LBBB
(Minnesota codes: ST-depression 4.1; 4.2;
ST-elevation 9.2; LBBB 7.1) and/or
(b) evidence of fresh thrombus by coronary angi-
ography and/or at autopsy,
but death occurring before blood samples could
be obtained or at a time before the appearance
of cardiac biomarkers in the blood, and there is
no evidence of a non-coronary cause of death.
or
(iii) Autopsy findings of an acute MI.
Category B definition and diagnostic criteria of MI if
the requirements for diagnostic tests in Category A
(above) have not been met. ICD-10 code: I 21
Whenever there is incomplete information on cardiac
biomarkers (preferably troponin) and other diagnostic
criteria needed to apply Category A, the term MI
should be used if:
(i) Both of the following criteria are present:
(a) symptoms of ischaemia (ischaemic symp-
toms include various combinations of
chest, upper extremity, jaw or epigastric
discomfort with exertion or at rest; the dis-
comfort usually lasts 420 min, often is dif-
fuse, not localized, not positional, not
affected by movement of the region, and
it may be accompanied by dyspnoea, dia-
phoresis, nausea or syncope) and
(b) development of unequivocal pathological
Q waves [no pathological Q wave in the
first ECG or in the event set of ECG/s fol-
lowed by a record with a pathological
Q wave—any Q wave in leads V2–V3
50.02 s (Minnesota code 1.2.1) or QS com-
plex in leads V2 and V3 (Minnesota code
1.2.7). Q-wave 50.03 s and 50.1 mV deep
(Minnesota codes 1.1.1; 1.2.2) or QS com-
plex in leads I, II, aVL, aVF or V4–V6 in any
two leads of a contiguous lead grouping I,
aVL, V6: V4–V6: II, III, aVF (Minnesota
codes 1.1.7; 1.3.6)].
or
142 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
(ii) Death with a history of coronary heart disease
and/or documented cardiac pain within 72 h
before death and no evidence of non-coronary
cause of death, or autopsy evidence of chronic
coronary heart disease, including coronary ath-
erosclerosis and myocardial scarring.
Category C definition and diagnostic criteria of
probable MI. ICD-10 code: I 24.9
In resource-constrained settings, individuals with MI
may not satisfy criteria of definitions in Category A
or B. This may be due to delayed access to medical
services and/or unavailability of electrocardiography
and/or lack of facilities for laboratory assay of specific
cardiac biomarkers.
The term probable MI should be used when there is
insufficient information to decide whether or not
there was an MI based on definitions in Categories
A and B above, but
(i) Either one of the following is present in a
person with symptoms of ischaemia (include
various combinations of chest, upper extremity,
jaw or epigastric discomfort with exertion or at
rest; the discomfort usually lasts 420 min,
often is diffuse, not localized, not positional,
not affected by movement of the region, and
it may be accompanied by dyspnoea, diaphor-
esis, nausea or syncope), with no evidence of a
non-coronary reason:
(a) development of unequivocal pathological Q
waves (no pathological Q wave in the first
ECG or in the event set of ECG/s followed
by a record with a pathological Q wave—
Minnesota codes 4.1; 4.2; 5.1; 5.2; 9.2—or
development of new ischaemia—new ST-T
changes and an equivocal change in Q
waves—Minnesota code 1.2.8 or any 1.3
code—demonstrated between the ECGs
associated with the event or between a pre-
viously recorded ECG and the event ECG);
or
(b) incomplete information on cardiac bio-
markers (preferably troponin) provided
that myocardial damage of other reasons
(Table 2) and other clinical conditions
that can cause a rise in cardiac biomarkers
are excluded.
or
(ii) Autopsy findings suggestive of MI but not
conclusive.
In all cases (including Categories A, B and C), sev-
eral biomarker [troponin or creatine kinase (CK)-MB]
determinations, which are all normal, exclude the
diagnoses of MI or probable MI.
Definition of a prior MI (same as the ESC/ACC/AHA/
WHF definition),14 ICD-10 code: I 25.2
The term prior MI should be used in the presence of
any one of the following:
(i) pathological Q waves [any Q wave in leads
V2–V3 50.02 s—Minnesota code 1.2.1—or QS
complex in leads V2 and V3—Minnesota code
1.2.7. Q-wave 50.03 s and 50.1 mV deep—
Minnesota codes 1.1.1; 1.2.2—or QS complex
in leads I, II, aVL, aVF or V4–V6 in any two
leads of a contiguous lead grouping I, aVL,
V6: V4–V6: II, III, aVF (Minnesota codes
1.1.7; 1.3.6)] with or without symptoms;
(ii) imaging evidence of a region of loss of viable
myocardium that is thinned and has a motion
abnormality, in the absence of a non-ischaemic
cause; and
(iii) pathological findings at autopsy of a healed or
healing MI.
Recurrent MI, ICD-10 code: I 22
Incident MI is defined as the person’s first MI ever.
When features of MI occur in the first 28 days after
an incident event, the event is not counted as a new
event for epidemiological purposes. If features of MI
occur after 28 days of an incident event, it is con-
sidered to be a new infarct (a recurrent event).
Reinfarction, ICD-10 code: I 21
The term reinfarction is used for an MI that occurs
within 28 days of an incident or a recurrent MI.
Fatal coronary heart disease is death with none of
the above and no other cause of death with any one
of the following:
(i) symptoms suggestive of myocardial ischaemia
(ischaemic symptoms include various combin-
ations of chest, upper extremity, jaw or epigas-
tric discomfort with exertion or at rest; the
discomfort usually lasts 420 min, often is dif-
fuse, not localized, not positional, not affected
by movement of the region, and it may be
accompanied by dyspnoea, diaphoresis, nausea
or syncope), including cardiac arrest;
(ii) documented history (based on clinical records
and ECG) of coronary heart disease; and
(iii) pathological findings of coronary atheroscler-
osis and myocardial scarring at autopsy.
Peri-procedural MI (same as the ESC/ACC/AHA/WHF
definition) (14), ICD-10 code: I 21
For percutaneous coronary interventions or coronary
artery bypass grafting in patients with normal base-
line troponin values, elevations of cardiac biomarkers
above the 99th percentile of upper reference limit are
indicative of peri-procedural myocardial necrosis.
By convention, for percutaneous coronary
interventions-related MI, cardiac biomarker values
three times greater than the 99th-percentile upper
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reference limit are considered diagnostic. It is essential
that the increases occur from a normal baseline. If
values are rising, distinguishing between the rise due
to the acute event (whether appreciated or not) or due
to the procedure itself is difficult.
By convention, for coronary artery bypass grafting–
related MI, cardiac biomarkers values five times
greater than the 99th-percentile upper reference
limit plus either new pathological Q waves or new
LBBB or angiographically documented new graft or
native coronary artery occlusion or imaging evidence
of new loss of viable myocardium are considered
diagnostic.
MI associated with stent thrombosis as documented
by angiography or autopsy.
Unstable angina
Unstable angina is diagnosed when there are new
or worsening symptoms of ischaemia (or changing
symptom pattern) and ischaemic ECG changes
(Minnesota codes 4.1; 4.2; 5.1; 5.2; 9.2) with normal
biomarkers. The distinction between new angina,
worsening angina and unstable angina is notoriously
difficult and based on a clinical assessment and a
careful and full clinical history.
Implications
So that there is uniformity in the reporting of data,
MIs should be reported as outlined above. In that
way, the outcomes of clinical trials and the findings
in registries across the globe can be applied and com-
pared more appropriately. There are many conditions
that confound the ECG diagnosis of MI and the diag-
nosis of MI using biomarkers (Tables 1 and 2).14
The Category C definition of probable MI is required
mainly because of inequities in access to health
services that prevail in low-resource settings.
Furthermore, in settings where resources are very
constrained, situations may arise where even the
tests required for a diagnosis of probable MI are
not available and other reasons for the symptoms
are not known. In countries where this is like-
ly to happen, the use of code ‘unclassifiable
MI’ should be considered for epidemiological
purposes.
When feasible, the diagnosis of acute MI should
be based on raised troponin levels because of the
sensitivity and specificity of these markers. Troponin
elevations are usually an indication of damaged
myocardial cells and cell death. Raised troponin
levels are associated with increased risks of death
and recurrent MI. Enzymes such as glutamine
oxaloacetic transaminase (aspartate aminotransferase)
and lactate dehydrogenase are still being used for
diagnosis of MI in some laboratories. CK has a wide
tissue distribution. If total CK is used for clinical
diagnosis of MI, the cut-off limits should be at least
twice the upper reference limit for CK; different
cut-off limits should be available for men and women
and other causes of an elevation of CK such as exercise
should be absent.18 CK-MB (measured by mass assay) is
less tissue specific than cardiac troponin. Assay of
non-specific cardiac biomarkers should be phased out
and replaced with CK-MB fraction or, preferably, with
troponin. However, given the critical financing issues
related to health care and other competing health
priorities in LMICs, it may take many years to bring
about such changes.
Table 1 Conditions that confound or simulate the ECG diagnosis of MI
ECG may be normal QS complex in lead V1
Q wave <0.03 s and <1/4 of the R wave amplitude in LIII is normal if the frontal
axis is 30 and 08
Q wave may be normal in aVL if the frontal QRS axis is between 60 and 908
Septal Q waves <0.03 s and <1/4 of the R wave amplitude in leads I, aVL, aVF,
V4 and V6
Q/QS complexes in
the absence of MI
Pre-excitation, obstructive or dialated cardiomyopathy, LBBB, left anterior
hemiblock, left and right ventricular hypertrophy and acute cor pulmonale





Metabolic disturbances such as hyperkalaemia
Failure to recognize normal limits for J-point
Lead transposition or displacement
Cholecystitis
False negatives Prior myocardial infarction with Q-waves and/or persistent ST elevation
Paced rhythm
LBBB
Source: Modified from ref. 14.
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There will be some advantages and disadvantages
with these revised definitions. For the individual
patient, the new definition may cause changes in
the eligibility to continue in certain occupations and
the ability of persons to obtain insurance. Many
patients who in the past would have been diagnosed
as having unstable angina will now be diagnosed as
having had an MI.
The application of the more sensitive new diagnostic
criteria for MI will cause the recorded incidence of MI
to rise and the case fatality to fall with a reduction in
false-positive and false-negative cases. This may
confuse efforts to follow trends in disease rates and
outcomes that are used to evaluate the impact of
public health measures and treatment.19–21 There will
be significant health resource and cost implications but
expenditures will be better directed as a consequence of
more accurate diagnosis, improved patient outcomes
and decreased mortality rates.
Comparison with previous epidemiological studies
using the old definition will be problematic. When
interpreting trends and comparing data collected in
different settings, there is a need to take note of the
different definitions that may have been used in
collecting the data. For accurate tracking of MI
rates, methods for adjusting the new criteria to the
old may be required. For example, specific surveil-
lance centres in LMICs may be needed to measure
total CK and CK-MB together with new biomarkers
for a transition period, or to apply both new and old
diagnostic criteria for a given period of time to assess
the difference in terms of incidence, prevalence and
mortality rates.
A specific problem for the assessment of event rates
and their trends in the population is death when
there is insufficient evidence to classify the event as
a coronary death, and there is no other known cause.
The number of such deaths may be substantial.10 It is
important for the epidemiological reporting that such
deaths are also monitored.
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